1. Show article details.

    VIVUS Announces Scientific Presentations

    Market Wire – 7:00 AM ET 05/14/2015

    05/14/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced the following scientific presentations: Conference AACE 2015: American Association of Clinical Endocrinologists 24 th Annual Scientific and Clinical CongressMay 13-17, 2015 Music...

  2. Show article details.

    VIVUS Reports First Quarter 2015 Financial Results

    Market Wire – 4:00 PM ET 05/05/2015

    05/05/15 -- VIVUS, Inc. (VVUS)  , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the first quarter ended March 31, 2015.

  3. Show article details.

    VIVUS Announces Date of First Quarter 2015 Update and Financial Results Conference Call

    GlobeNewswire – 7:00 AM ET 04/30/2015

    VIVUS, Inc. (VVUS) today announced that it will provide an update and report financial results for the first quarter ended March 31, 2015 after the NASDAQ Market closes on Tuesday, May 5, 2015. Date: May 5, 2015 Time: 4:30 PM ET Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=68930&k=0C92CB20.

  4. Show article details.

    VIVUS Announces New Discount Program Through Sam's Club for Qsymia Patients

    Market Wire – 7:00 AM ET 04/28/2015

    04/28/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing Qsymia® capsules CIV for the treatment of obesity, today announced that effective May 1, 2015, Qsymia will be the sole anti-obesity agent available on the Sam's Club Extra Value Drug List. "We are pleased with this new, exclusive agreement between Sam's Club and VIVUS," said Seth H. Z. Fischer, CEO.

  5. Show article details.

    VIVUS Announces Issuance of Two Additional U.S. Patents for Qsymia

    Market Wire – 4:30 PM ET 04/21/2015

    04/21/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced that the United States Patent and Trademark Office has issued U.S. Patent Nos.

  6. Show article details.

    VIVUS Files Lawsuit Against Teva for Infringement of Qsymia Patents

    Market Wire – 7:30 PM ET 04/15/2015

    04/15/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced that it has filed a lawsuit in the U.S. District Court for the District of New Jersey against Teva Pharmaceuticals USA, Inc. and Teva Pharmaceutical Industries, Ltd., collectively re...

  7. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 04/10/2015

    04/10/15 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: 14th Annual Needham Healthcare Conference April 14, 2015, 3:40pm EDT The Westin Grand Central Hotel, New York, NY. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

  8. Show article details.

    Japanese Drug Company Eisai to Cut 25% of U.S. Jobs

    DJ Business News – 7:05 PM ET 04/09/2015

    Japanese pharmaceutical company Eisai Inc. said Thursday that it would cut about 25% of its U.S. workforce as part of a plan to restructure its operations in the country. "The actions we are taking will ensure Eisai (ESALF) stays competitive in a rapidly changing business environment," Chief Executive Yuji Matsue said in a news release, adding that the company is "fully committed to the U.S. market." Eisai (ESALF) said it had no plans to close any of its main offices or facilities.

  9. Show article details.

    VIVUS Announces Operational Update

    Market Wire – 4:05 PM ET 03/30/2015

    03/30/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today announced an operational update, including certain key corporate decisions and plans regarding Qsymia® capsules CIV.

  10. Show article details.

    VIVUS Reports Fourth Quarter and Year-End 2014 Financial Results

    Market Wire – 4:00 PM ET 02/24/2015

    02/24/15 -- VIVUS, Inc. (VVUS) , a biopharmaceutical company commercializing and developing innovative, next-generation therapies to address unmet needs in obesity, sleep apnea, diabetes and sexual health, today provided a business update and reported its financial results for the fourth quarter and year ended December 31, 2014.

  11. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 02/20/2015

    02/20/15 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: 2015 RBC Capital Markets' Global Healthcare Conference February 25, 2015, 3:35pm EST New York Palace Hotel, New York, NY. A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

  12. Show article details.

    VIVUS Announces Date of Fourth Quarter and Year End 2014 Update and Financial Results Conference Call

    GlobeNewswire – 7:00 AM ET 02/19/2015

    VIVUS, Inc. (VVUS) today announced that it will report financial results for the fourth quarter and year ended December 31, 2014 after the NASDAQ Market closes on Tuesday, February 24, 2015. Date: February 24, 2015 Time: 4:30 PM EST. Listen via Internet: http://ir.vivus.com/ Schedule this webcast into MS-Outlook calendar: http://apps.shareholder.com/PNWOutlook/t.aspx?m=67953&k=64288A08.

  13. Show article details.

    VIVUS Announces European Approval of SPEDRA Label Amendment; SPEDRA Now First and Only Oral Erectile Dysfunction Treatment Approved in Europe to Be Taken Approximately 15 Minutes Before Sexual Activity

    Market Wire – 7:00 AM ET 01/29/2015

    01/29/15 -- VIVUS, Inc. (VVUS) today announced that the European Commission has adopted the commission implementing decision amending the marketing authorization for SPEDRA. "We are pleased with the EC decision to approve the label amendment for SPEDRA," said Seth H. Z. Fischer, Chief Executive Officer of VIVUS.

  14. Show article details.

    VIVUS to Present at Upcoming Investor Conference

    Market Wire – 7:00 AM ET 01/09/2015

    01/09/15 -- VIVUS, Inc. (VVUS) today announced that management will present an overview of the company at the following investment conference: 33rd Annual J.P. Morgan Healthcare Conference January 15, 2015, 9:00am PST Westin St. Francis Hotel, San Francisco, California A live webcast and 30-day archive of the presentation will be available at http://ir.vivus.com.

Page:

Today's and Upcoming Events

  • Aug
    4

    VVUS to announce Q2 earnings After Market (Unconfirmed)

Past Events (last 90 days)

No events in the past 90 days

Data provided by Wall Street Horizon, Inc. © 2015

Technical Events

Technical Analysis

PROVIDED BY TRADING CENTRAL
As with all your investments through Fidelity, you must make your own determination whether an investment is appropriate for you. Fidelity is not recommending or endorsing this security by making it available to customers. You should conduct research and perform a thorough investigation as to the characteristics of any securities you intend to purchase. Before investing, you should read the prospectus, offering circular, indenture, or similar document carefully for a full description of the product, including its features and risks, to determine whether it is an appropriate investment for your investment objectives, risk tolerance, financial situation and other individual factors, and be sure to re-evaluate those factors on a periodic basis.

Performance data shown represents past performance, which is no guarantee of future results. Current performance may be higher or lower than the performance data quoted. Yield and return will vary, therefore, you may have a gain or loss when you sell your shares.


Stock markets are volatile and can decline significantly in response to adverse issuer, political, regulatory, market, or economic developments. Growth stocks can be more volatile than other types of stocks. Value stocks can continue to be undervalued by the market for long periods of time. Foreign securities are subject to interest-rate, currency-exchange-rate, economic, and political risks, all of which are magnified in emerging markets. Illiquidity is an inherent risk associated with investing in real estate and REITs. There is no guarantee the issuer of a REIT will maintain the secondary market for its shares and redemptions may be at a price which is more or less than the original price paid. Closed-end funds can trade at a discount to their NAV. Shareholders of Master Limited Partnerships may be treated as partners for tax purposes. Partnerships issue a Schedule K-1 (Form 1065) rather than a Form 1099 form for tax purposes. It lists the partner's share of income, deductions, credits, etc. Speak with your tax advisor to determine how this may affect you. A royalty trust is a type of corporation, mostly in the United States or Canada, usually involved in oil and gas production or mining. Royalty trusts may have special tax treatment, so you should consult a tax advisor on the potential tax consequences of investing in them.

News, commentary and events are from third-party sources unaffiliated with Fidelity. Fidelity does not endorse or adopt their content. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from their use.

Any data, charts and other information provided on this page are intended for research purposes to help self-directed investors evaluate many types of securities including, but not limited to common stocks, American Depository Receipts, Master Limited Partnerships, real estate investment trusts. traditional preferred stock, trust preferred securities, third-party trust certificates, convertible securities, mandatory convertible securities and other exchange-traded equity and/or debt securities. Criteria and inputs entered, including the choice to make security comparisons, are at the sole discretion of the user and are solely for the convenience of the user. Analyst opinions, ratings and reports are provided by third-parties unaffiliated with Fidelity. All information supplied or obtained from this page is for informational purposes only and should not be considered investment advice or guidance, an offer of or a solicitation of an offer to buy or sell a security, or a recommendation or endorsement by Fidelity of any security or investment strategy. Fidelity does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities. Fidelity makes no guarantees that information supplied is accurate, complete, or timely, and does not provide any warranties regarding results obtained from its use.